Neuros Technology

Neuros Medical, Inc. Names David Veino as President and CEO and Expands Board of Directors

Retrieved on: 
Monday, October 23, 2023
Ban, Abbott, FDA, NYSE, Stryker, Physician, General partnership, PMA, Inspiration, Amputation, Quality of life, U.S. Venture Partners, USVP, Patient, Obstructive sleep apnea, Management, Pharmaceutical industry, Nursing, Neuros Technology

In this planned transition, Veino will join the Board of Directors.

Key Points: 
  • In this planned transition, Veino will join the Board of Directors.
  • Upon anticipated PMA approval from the FDA, Veino will lead the transition of Neuros from an early-stage company to its commercial execution stage, and beyond.
  • "The Neuros team is thrilled to have Randy join our Board," says Veino.
  • Ban joins a highly engaged, talented Board of Directors with a mission of delivering Neuros' innovative technology to physicians and their patients who are seeking relief from chronic post-amputation pain.

Neuros Medical Announces Completion of QUEST Pivotal Trial 90-day Primary Endpoints

Retrieved on: 
Monday, June 6, 2022
Gabapentinoid, CA, Company, IDE, Doctor of Philosophy, Neuros Technology, BSI, International Organization for Standardization, Pain, QUEST, O'Berry Neuro-Medical Center, Sale, Patient, ISO, Phantom limb, Technology, Chronic pain, Autumn, IPG, Peripheral nervous system, Certification, Safety, Medical device, Poultry, ALTIUS

ALISO VIEJO, Calif., June 6, 2022 /PRNewswire/ -- Neuros Medical, Inc., a medical device company developing an innovative, on-demand bioelectric nerve block therapy for patients with intractable post-amputation pain, announced today the completion of its QUEST Pivotal Trial 90-day primary endpoints.

Key Points: 
  • ALISO VIEJO, Calif., June 6, 2022 /PRNewswire/ -- Neuros Medical, Inc., a medical device company developing an innovative, on-demand bioelectric nerve block therapy for patients with intractable post-amputation pain, announced today the completion of its QUEST Pivotal Trial 90-day primary endpoints.
  • QUEST is a 180-subject randomized, double blinded, active sham controlled clinical trial that is being conducted under an Investigational Device Exemption (IDE).
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusBioelectric Nerve Block Technology to treat intractable post-amputation pain.
  • Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.

Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

Retrieved on: 
Wednesday, September 15, 2021
Case Western Reserve University, Gabapentinoid, IDE, DRS, O'Berry Neuro-Medical Center, Patient, Phantom, Company, Phantom limb, QUEST, Safety, Peripheral nervous system, Joe Byrd (Cherokee Nation Principal Chief), Neuros Technology, Chronic pain, Pain, IPG, Poultry, Medical device

QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.

Key Points: 
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.
  • Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.
  • Neuros Medical, a neuromodulation company, has developed the Altius system for the treatment of chronic post-amputation pain (phantom limb pain and residual limb pain).
  • Post-amputation pain includes both phantom limb and residual limb (or "stump") pain, and impacts nearly one million Americans.

ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel

Retrieved on: 
Wednesday, March 24, 2021
Neuros Technology, Lluís Companys, Spanish politicians, Government of Spain

Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuros Chief Executive Officer, and serve as a member of the Companys senior leadership team.

Key Points: 
  • Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuros Chief Executive Officer, and serve as a member of the Companys senior leadership team.
  • Ellisa is a tremendous addition to our capable and growing leadership team, commented Joe Burnett, President and CEO of ClearPoint Neuro.
  • Ms. Cholapranee brings to the Company almost a decade of experience advising companies in the life science and medical device sectors on legal, business, and compliance issues.
  • I am thrilled to join ClearPoint at such an exciting phase of the Companys growth, stated Ellisa Cholapranee.

Biotechnology Leader and Surgeon Dr. Matthew Klein Joins ClearPoint Neuro Board of Directors

Retrieved on: 
Friday, April 17, 2020
Neuros Technology, PTC, Neuro, Video games

IRVINE, Calif., April 17, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuros Board of Directors effective immediately.

Key Points: 
  • IRVINE, Calif., April 17, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuros Board of Directors effective immediately.
  • Dr. Klein, Chief Development Officer of PTC Therapeutics, Inc. (PTC), is a veteran biotechnology company executive with extensive experience in drug discovery and development, and a board-certified surgeon.
  • He succeeds Marcio Souza, who joined ClearPoint Neuros Board as PTCs representative in connection with PTCs May 2019 equity investment in ClearPoint Neuro.
  • The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the United States.